Effects of antisense peptide nucleic acid to platelet-derived growth factor A-chain on growth of vascular smooth muscle cells

Noboru Fukuda; Rie Furuya; Hirobumi Kishioka; Ryo Suzuki; Hiroyuki Matsuda; Yoshiko Tahira; Hiroto Takagi; Yukihiro Ikeda; Satoshi Saito; Koichi Matsumoto; Katsuo Kanmatsuse

doi:10.1097/00005344-200308000-00011

Effects of antisense peptide nucleic acid to platelet-derived growth factor A-chain on growth of vascular smooth muscle cells

Noboru Fukuda, Rie Furuya, Hirobumi Kishioka, Ryo Suzuki, Hiroyuki Matsuda, Yoshiko Tahira, Hiroto Takagi, Yukihiro Ikeda, Satoshi Saito, Koichi Matsumoto, Katsuo Kanmatsuse

School of Medicine

Nihon University

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

To investigate antisense peptide nucleic acid (PNA) as a gene therapy for the arterial proliferative diseases, the authors designed and examined the effects of an antisense PNA targeting platelet-derived growth factor (PDGF) A-chain on expression of PDGF A-chain and growth of vascular smooth muscle cells (VSMCs) from spontaneously hypertensive rats. A 15-mer antisense PNA complementary to the initiation codon of rat and human PDGF A-chain mRNA was synthesized and purified by high-performance liquid chromatography. Gel-shift assay and biomolecular interaction analysis (BIAcore) revealed that the antisense PNA bound weakly to the target RNA, whereas it bound strongly to the target DNA. Fluorescein-isothiocyanate-labeled antisense PNA to PDGF A-chain was taken up slowly and maintained in VSMCs for a prolonged period of time. Antisense PNA inhibited expression of PDGF A-chain mRNA and protein as well as DNA synthesis in VSMCs in a dose-independent manner. Inhibition of DNA synthesis by the antisense PNA was greater than that by the antisense DNA at a low concentration (0.5 μmol/L). These results suggest that antisense PNA to PDGF A-chain will be used as a gene therapy for vascular proliferative diseases such as hypertensive vascular diseases, restenosis of coronary arteries after angioplasty, and atherosclerosis.

Original language	English
Pages (from-to)	224-231
Number of pages	8
Journal	Journal of Cardiovascular Pharmacology
Volume	42
Issue number	2
DOIs	https://doi.org/10.1097/00005344-200308000-00011
Publication status	Published - 1 Aug 2003

Keywords

Gene therapy
Growth
Peptide nucleic acid
Platelet-derived growth factor
Vascular smooth muscle

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/00005344-200308000-00011

Cite this

Fukuda, N., Furuya, R., Kishioka, H., Suzuki, R., Matsuda, H., Tahira, Y., Takagi, H., Ikeda, Y., Saito, S., Matsumoto, K., & Kanmatsuse, K. (2003). Effects of antisense peptide nucleic acid to platelet-derived growth factor A-chain on growth of vascular smooth muscle cells. Journal of Cardiovascular Pharmacology, 42(2), 224-231. https://doi.org/10.1097/00005344-200308000-00011

@article{334c68bd612e4d398db953f72c5a2e77,

title = "Effects of antisense peptide nucleic acid to platelet-derived growth factor A-chain on growth of vascular smooth muscle cells",

abstract = "To investigate antisense peptide nucleic acid (PNA) as a gene therapy for the arterial proliferative diseases, the authors designed and examined the effects of an antisense PNA targeting platelet-derived growth factor (PDGF) A-chain on expression of PDGF A-chain and growth of vascular smooth muscle cells (VSMCs) from spontaneously hypertensive rats. A 15-mer antisense PNA complementary to the initiation codon of rat and human PDGF A-chain mRNA was synthesized and purified by high-performance liquid chromatography. Gel-shift assay and biomolecular interaction analysis (BIAcore) revealed that the antisense PNA bound weakly to the target RNA, whereas it bound strongly to the target DNA. Fluorescein-isothiocyanate-labeled antisense PNA to PDGF A-chain was taken up slowly and maintained in VSMCs for a prolonged period of time. Antisense PNA inhibited expression of PDGF A-chain mRNA and protein as well as DNA synthesis in VSMCs in a dose-independent manner. Inhibition of DNA synthesis by the antisense PNA was greater than that by the antisense DNA at a low concentration (0.5 μmol/L). These results suggest that antisense PNA to PDGF A-chain will be used as a gene therapy for vascular proliferative diseases such as hypertensive vascular diseases, restenosis of coronary arteries after angioplasty, and atherosclerosis.",

keywords = "Gene therapy, Growth, Peptide nucleic acid, Platelet-derived growth factor, Vascular smooth muscle",

author = "Noboru Fukuda and Rie Furuya and Hirobumi Kishioka and Ryo Suzuki and Hiroyuki Matsuda and Yoshiko Tahira and Hiroto Takagi and Yukihiro Ikeda and Satoshi Saito and Koichi Matsumoto and Katsuo Kanmatsuse",

year = "2003",

month = aug,

day = "1",

doi = "10.1097/00005344-200308000-00011",

language = "English",

volume = "42",

pages = "224--231",

journal = "Journal of Cardiovascular Pharmacology",

issn = "0160-2446",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

Fukuda, N, Furuya, R, Kishioka, H, Suzuki, R, Matsuda, H, Tahira, Y, Takagi, H, Ikeda, Y, Saito, S, Matsumoto, K & Kanmatsuse, K 2003, 'Effects of antisense peptide nucleic acid to platelet-derived growth factor A-chain on growth of vascular smooth muscle cells', Journal of Cardiovascular Pharmacology, vol. 42, no. 2, pp. 224-231. https://doi.org/10.1097/00005344-200308000-00011

TY - JOUR

T1 - Effects of antisense peptide nucleic acid to platelet-derived growth factor A-chain on growth of vascular smooth muscle cells

AU - Fukuda, Noboru

AU - Furuya, Rie

AU - Kishioka, Hirobumi

AU - Suzuki, Ryo

AU - Matsuda, Hiroyuki

AU - Tahira, Yoshiko

AU - Takagi, Hiroto

AU - Ikeda, Yukihiro

AU - Saito, Satoshi

AU - Matsumoto, Koichi

AU - Kanmatsuse, Katsuo

PY - 2003/8/1

Y1 - 2003/8/1

N2 - To investigate antisense peptide nucleic acid (PNA) as a gene therapy for the arterial proliferative diseases, the authors designed and examined the effects of an antisense PNA targeting platelet-derived growth factor (PDGF) A-chain on expression of PDGF A-chain and growth of vascular smooth muscle cells (VSMCs) from spontaneously hypertensive rats. A 15-mer antisense PNA complementary to the initiation codon of rat and human PDGF A-chain mRNA was synthesized and purified by high-performance liquid chromatography. Gel-shift assay and biomolecular interaction analysis (BIAcore) revealed that the antisense PNA bound weakly to the target RNA, whereas it bound strongly to the target DNA. Fluorescein-isothiocyanate-labeled antisense PNA to PDGF A-chain was taken up slowly and maintained in VSMCs for a prolonged period of time. Antisense PNA inhibited expression of PDGF A-chain mRNA and protein as well as DNA synthesis in VSMCs in a dose-independent manner. Inhibition of DNA synthesis by the antisense PNA was greater than that by the antisense DNA at a low concentration (0.5 μmol/L). These results suggest that antisense PNA to PDGF A-chain will be used as a gene therapy for vascular proliferative diseases such as hypertensive vascular diseases, restenosis of coronary arteries after angioplasty, and atherosclerosis.

AB - To investigate antisense peptide nucleic acid (PNA) as a gene therapy for the arterial proliferative diseases, the authors designed and examined the effects of an antisense PNA targeting platelet-derived growth factor (PDGF) A-chain on expression of PDGF A-chain and growth of vascular smooth muscle cells (VSMCs) from spontaneously hypertensive rats. A 15-mer antisense PNA complementary to the initiation codon of rat and human PDGF A-chain mRNA was synthesized and purified by high-performance liquid chromatography. Gel-shift assay and biomolecular interaction analysis (BIAcore) revealed that the antisense PNA bound weakly to the target RNA, whereas it bound strongly to the target DNA. Fluorescein-isothiocyanate-labeled antisense PNA to PDGF A-chain was taken up slowly and maintained in VSMCs for a prolonged period of time. Antisense PNA inhibited expression of PDGF A-chain mRNA and protein as well as DNA synthesis in VSMCs in a dose-independent manner. Inhibition of DNA synthesis by the antisense PNA was greater than that by the antisense DNA at a low concentration (0.5 μmol/L). These results suggest that antisense PNA to PDGF A-chain will be used as a gene therapy for vascular proliferative diseases such as hypertensive vascular diseases, restenosis of coronary arteries after angioplasty, and atherosclerosis.

KW - Gene therapy

KW - Growth

KW - Peptide nucleic acid

KW - Platelet-derived growth factor

KW - Vascular smooth muscle

UR - http://www.scopus.com/inward/record.url?scp=10744227345&partnerID=8YFLogxK

U2 - 10.1097/00005344-200308000-00011

DO - 10.1097/00005344-200308000-00011

M3 - Article

C2 - 12883326

AN - SCOPUS:10744227345

SN - 0160-2446

VL - 42

SP - 224

EP - 231

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

IS - 2

ER -

Effects of antisense peptide nucleic acid to platelet-derived growth factor A-chain on growth of vascular smooth muscle cells

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this